The technology employs CRISPR/Cas9 mutagenesis to create genetically modified mice that express truncated versions of the Tim-3 protein under the control of its native promoter. The modifications are maintained on a pure C57BL/6 genetic background, ensuring physiological expression levels. The mice are viable, fertile, and adhere to Mendelian inheritance ratios. This refined model exhibits Tim-3 expression solely as the truncated variant on immune cell surfaces, offering a precise tool for studying Tim-3 signaling in diverse immune response contexts without the interference of wild-type protein.
Description
This approach stands out due to its meticulous control of genetic background and exclusive expression of the truncated Tim-3 protein. Unlike previous models, no wild-type version is co-expressed, which eliminates potential confounding factors in experimental outcomes. This clarity enhances the understanding of Tim-3’s role in immune responses, anti-tumor immunity, and infection control. Additionally, maintaining the native promoter control ensures that the study of immune regulation remains physiologically relevant, making the technology a valuable asset for targeted mechanistic investigations and therapeutic developments in immunology.
Applications
- Immunotherapy drug screening
- Preclinical immune checkpoint testing
- Cancer immunotherapy development
- Immunomodulatory antibody testing
- Infection response evaluation
Advantages
- Maintains physiological control of truncated Tim-3 expression for authentic immune signaling studies.
- Uses a pure C57BL/6 genetic background to enhance reproducibility and reliability.
- Eliminates wild-type Tim-3 expression, reducing experimental interference.
- Provides a refined model for investigating immune responses and potential therapeutic strategies.
IP Status
Research Tool
